MD
Professor of Surgery and Pharmacology; Oliver Smithies Investigator
Co-Leader, UNC Lineberger Clinical Research Program
Director, UNC Lineberger Pancreatic Cancer Center of Excellence
Vice Chair for Research, Department of Surgery
UNC-Chapel Hill
Clinical Research
Gastrointestinal Oncology Program, UNC Lineberger Pancreatic Cancer Center of Excellence
Area of Interest
Jen Jen Yeh, MD, maintains an active clinical practice taking care of patients with endocrine (thyroid, parathyroid and adrenal) diseases and pancreatic cancer. Her research focus centers on the use of genomics to identify new approaches for pancreatic cancer.
Yeh received her medical degree from Johns Hopkins University and completed her general surgery residency at the Boston Medical Center, a research fellowship at Dana-Farber Cancer Institute, and a surgical oncology fellowship at the Memorial-Sloan Kettering Cancer Center.
In 2015, Yeh identified new molecular subtypes of pancreatic cancer that have may have biological and clinical significance. To translate molecular subtypes to the clinic, her group developed a single sample classifier that is now being developed for clinical use. Yeh and her collaborators also have developed a device that could help drive chemotherapy drugs directly into pancreatic tumor tissue to prevent their growth and shrink them. Yeh co-founded Advanced Chemotherapeutic Technologies, Inc. in order to bring the device into clinical trials. Yeh’s group is focused on identifying vulnerabilities in tumors to guide treatment for patients.
News and Stories
UNC researchers present at American Association for Cancer Research’s 115th Annual Meeting
Researchers and trainees from UNC and UNC Lineberger at will present more than 30 talks and participate in scientific and educational panels and discussions on the latest cancer research.
Yeh, Johnson awarded five-year, $3.2 million research grant from NCI
The grant will support the first metastatic pancreatic cancer trial in the country to evaluate whether selecting treatment by tumor subtype will help patients match to more effective first-line therapies.